Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone

被引:47
作者
Toyoda, Yutaka [1 ]
Shinohara, Nobuo [1 ]
Harabayashi, Toru [1 ]
Abe, Takashige [1 ]
Akino, Tomoshige [1 ]
Sazawa, Ataru [1 ]
Nonomura, Katsuya [1 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Urol, Sapporo, Hokkaido, Japan
关键词
renal cell carcinoma; bone metastasis; prognosis; local management;
D O I
10.1016/j.eururo.2006.10.060
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We retrospectively analyzed the survival of renal cell carcinoma patients with bone metastases, and identified prognostic factors and a model predictive for survival in these patients. Methods: Fifty patients with renal cell carcinoma with osseous metastases were treated at Hokkaido University Hospital between 1980 and 2004. The relationship between several clinical features and survival was examined univariately. The Cox proportional hazards model was then used to form a multivariate model. Results: The median survival time from the diagnosis of bone metastasis was 12 mo, and overall survival at 2 yr was 37%. Clinical features correlated with longer survival in the multivariate analysis were a long interval (24 mo or more) between the diagnosis of kidney cancer and that of osseous metastasis (hazard ratio [HR]: 2.608; 95% confidence inter-Val [CI], 1.031-6.S99) and the absence of extraosseous metastases (HR: 2.523; 95%CI, 1.023-6.220). By combining these two favorable factors, renal cell carcinoma patients with osseous metastases could be categorized into two different groups. The median time to death in 20 patients with zero favorable factors (poor prognosis) was S mo. On the other hand, 30 patients had one or two favorable factors (good prognosis); the median survival time in this group was 30 mo. There was a significant difference in survival duration between the two groups (p < 0.001). Conclusions: Two prognostic factors predicting survival were identified and used to categorize renal cell carcinoma patients with bone metastasis into two prognostic groups. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 28 条
[1]  
Althausen P, 1997, CANCER, V80, P1103
[2]  
Citterio G, 1997, EUR UROL, V31, P286
[3]  
Cox D.R., 1990, ANAL SURVIVAL DATA
[4]  
FISHER RI, 2000, CANCER J SCI AM, V6, P555
[5]   Metastatic renal cell carcinoma [J].
Robert C. Flanigan ;
Steven C. Campbell ;
Joseph I. Clark ;
Maria M. Picken .
Current Treatment Options in Oncology, 2003, 4 (5) :385-390
[6]   Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma [J].
Han, KR ;
Pantuck, AJ ;
Bui, MHT ;
Shvarts, O ;
Freitas, DG ;
Zisman, A ;
Leibovich, BC ;
Dorey, FJ ;
Gitlitz, BJ ;
Figlin, RA ;
Belldegrun, AS .
UROLOGY, 2003, 61 (02) :314-319
[7]   Treatment of osseous metastases in patients with renal cell carcinoma [J].
Jung, ST ;
Ghert, MA ;
Harrelson, JM ;
Scully, SP .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (409) :223-231
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer [J].
Kuczyk, MA ;
Anastasiadis, AG ;
Zimmermann, R ;
Merseburger, AS ;
Corvin, S ;
Stenzl, A .
BJU INTERNATIONAL, 2005, 96 (05) :721-727
[10]   A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials [J].
Leibovich, BC ;
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Frank, I ;
Kwon, ED ;
Merchan, JR ;
Blute, ML .
JOURNAL OF UROLOGY, 2005, 174 (05) :1759-1763